Patisiran: Completed Phase III enrollment

Alnylam completed enrollment of 225 patients with stage 1 or 2 FAP in the double-blind, placebo-controlled, international Phase III APOLLO trial evaluating 0.3 mg/kg IV patisiran every 3 weeks for 18 months. FAP is a predominant clinical manifestation of TTR-mediated amyloidosis. ...